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Purpose: This study assessed the outcomes of ultrasound (US)-guided core needle biopsies (CNBs) 
of breast lesions with at least 2 years of follow-up to determine the false-negative rate and to 
evaluate the diagnostic accuracy of CNB.
Methods: We retrospectively analyzed 13,254 consecutive US-guided 14-gauge CNBs for breast 
lesions. We excluded biopsies if non-malignant biopsy result was not confirmed by surgical 
excision or US-guided vacuum-assisted biopsy, or fewer than 2 years of follow-up data were 
available. A total of 4,186 biopsies were excluded, and 9,068 breast masses from 7,039 women 
were included. The pathologic findings from each CNB were assessed using the standard 
diagnostic reference, defined based on the results of surgical excision, vacuum-assisted biopsy, 
or at least 2 years of long-term imaging follow-up. The false-negative rate and underestimation 
rate were calculated.
Results: Of the 9,068 CNBs, benign pathology was found in 64.2%, high-risk results in 3.5%, 
and malignant results in 32.3%. Of the 5,821 benign CNBs, an additional malignancy was 
found at excision in 63 lesions, leading to a false-negative rate of 2.0% (63 of 3,067). The 
underestimation rate was 33.6% (111 of 330) for ductal carcinoma in situ and 24.5% (79 of 
322) for high-risk results at surgical excision. Most false-negative diagnoses (84.1%, 53 of 
63) were recognized through imaging-histology correlations, and immediate rebiopsies were 
performed. Ten malignancies (15.9%, 10 of 63) had delayed diagnoses and showed progression 
in follow-up US imaging.
Conclusion: US-guided 14-gauge CNB provided optimal diagnostic information. Imaging-
histology correlations and appropriate imaging follow-up should be performed to avoid delayed 
diagnoses.
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Introduction
Imaging-guided core needle biopsy (CNB) is becoming the standard of diagnosis for breast disease 
as a reliable alternative to open excision biopsy [1-5]. Percutaneous image-guided CNB is performed 
under either stereotactic or ultrasonographic guidance. Percutaneous ultrasound (US)-guided breast 
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biopsy has several advantages over stereotactic or surgical biopsy, 
and many studies have reported CNB to be effective and safe. 
This procedure is safe; faster; less expensive; is performed in real 
time, allowing accurate assessments; and does not involve ionizing 
radiation [4,6,7].
However, the possibility of false-negative results is unavoidable; 
false-negatives can result from core needle sampling errors, failure 
to recognize imaging-histology discordances, and inappropriate 
follow-up periods for benign biopsies [8,9]. A delayed diagnosis of 
breast cancer is an outcome that every clinician strives to avoid. In 
previous studies of US-guided 14-gauge CNBs with at least 2 years 
of follow-up, the false-negative rates has ranged from 0.1% to 2.5% 
[5,10-12]. So far, some studies have been published on US-guided 
CNB for breast lesions with long-term follow-up periods [5,6,13,14], 
but most previous reports of US-guided CNB in the breast were 
based on a small number of biopsies. Furthermore, few studies have 
reported large series of US-guided CNB with long-term follow-up; 
therefore, this study was undertaken, based on a relatively large 
series of US-guided 14-gauge CNB procedures performed for breast 
lesions with long-term follow-up periods.
The purpose of this study was to assess the outcomes of US-
guided CNB for breast lesions that had at least a 2-year follow-up 
for benign lesions in a large series to determine the false-negative 
rate and to evaluate the diagnostic performance of CNB.
Materials and Methods
Study Population
This study was conducted with Institutional Review Board approval, 
and informed consent was waived because of the retrospective 
nature of this study.
From July 2005 to December 2012, 13,254 consecutive US-guided 
14-gauge CNBs for breast lesions were performed at our institution. 
We retrospectively reviewed all the biopsy results and excluded 4,186 
biopsies for which a non-malignant biopsy result was not confirmed 
by surgical excision or US-guided vacuum-assisted biopsy, or at least 
2 years of follow-up data were not available.
A total of 9,068 breast masses in 7,039 women (age range, 11 
to 92 years; mean, 46 years) were included in this study. Of the 
7,039 patients, 1,253 had biopsies of two separate lesions, 234 had 
biopsies of three separate lesions, 74 had biopsies of four separate 
lesions, 11 had biopsies of five separate lesions, four had biopsies of 
six separate lesions, one had biopsies of seven separate lesions, one 
had biopsies of eight separate lesions, and one had biopsies of 10 
separate lesions. 
Biopsy Procedure
US-guided 14-gauge CNB was performed using a free-hand 
technique and a high-resolution US unit with 7.5- or 12-MHz 
linear array transducers (HDI 5000 or IU22, Philips-Advanced 
Technology Laboratories, Bothell, WA, USA; or Logiq 9, GE 
Healthcare, Milwaukee, WI, USA). Each procedure was performed in 
an outpatient setting under local anesthesia with the patient in the 
supine position. A 14-gauge automated core biopsy needle with a 
spring-loaded biopsy gun (Promac 2.2L, Manan Medical Products, 
Northbrook, IL, USA) or a 14-gauge dual-action semiautomatic core 
biopsy needle with a 22-mm throw (Stericut cut with coaxial, TSK 
Laboratory, Tochigi, Japan) was used. All biopsies were performed 
by one of 19 radiologists in fellowship training (n=15) or with 
extensive clinical experience (n=4) who were specialists in breast 
imaging and biopsies. According to our standard protocol, four or 
five core samples per lesion were routinely obtained. 
Post-biopsy Procedure
For each lesion that underwent a CNB, a radiologist reviewed the 
pathology report in conjunction with the images obtained before, 
during, and after the biopsy procedure, and based on the results 
of the review, an addendum was attached to the biopsy report 
recommending specific management strategies for the patients 
and the referring physicians [15,16]. The imaging and histological 
findings were considered to be concordant when the histological 
findings provided a sufficient explanation for the imaging findings 
and discordant when they did not [15]. For malignant lesions (e.g., 
invasive carcinoma, ductal carcinoma in situ [DCIS], and metastases) 
identified through 14-gauge CNB, immediate definitive surgery or 
chemotherapy was recommended, in accordance with what was 
deemed clinically appropriate. For high-risk lesions (e.g., atypia 
including atypical ductal hyperplasia [ADH], lobular neoplasia, radial 
sclerosing lesions, and possible phyllodes tumors) and benign lesions 
(neither malignant nor high-risk) with imaging-histology discordance 
(i.e., a lesion that was thought to be malignant based on imaging 
but was demonstrated to be benign by histological findings) resulted 
in recommendations for surgical excision [15,17].
US follow-up at 6 months after biopsy and then annually for at 
least 2 years was recommended in patients with concordant benign 
lesions (i.e., a lesion that was suspected of being benign based on 
imaging and also proven to be benign by the histological findings). 
For some concordant benign lesions, rebiopsies were carried out 
by surgical excision or US-guided vacuum-assisted biopsy at the 
request by the patient or referring physician or because of suspicious 
physical findings (i.e., a palpable mass or nipple discharge) or 
lesion progression at US follow-up. The choice of surgical excision 
or US-guided vacuum-assisted biopsy at rebiopsy depended on the 
US-guided core biopsy of breast
e-ultrasonography.org Ultrasonography 37(1), January 2018 57
patient’s or referring physician’s preferences.
Data Analysis
The pathologic findings of US-guided 14-gauge CNBs and 
rebiopsies, as well as the follow-up results, were obtained from 
patients’ medical records. After reviewing the results, pathologic 
comparisons between US-guided 14-gauge CNB results and the 
standard diagnostic reference were made. The standard diagnostic 
reference included the results of surgical excision, vacuum-assisted 
biopsy, or at least 2 years of long-term imaging follow-up. The false-
negative rate was calculated as the proportion of benign results 
from US-guided 14-gauge CNBs among all breast cancers [5,10]. 
The underestimation rate for high-risk lesions was calculated as 
the proportion of lesions diagnosed as high-risk by CNB that were 
finally proven to be DCIS or invasive cancer after surgical excision. 
The underestimation rate for DCIS was likewise defined as the 
proportion of lesions diagnosed as DCIS by CNB that were finally 
proven to be invasive cancer after surgical excision [5]. For the false-
negative results of US-guided 14-gauge CNB, the time interval 
between the CNB and rebiopsy, as well as the reasons for rebiopsy, 
were reviewed.
Results
The lesions ranged in size from 2 to 130 mm (mean, 14.0 mm) 
as measured by US. The distribution of size and Breast Imaging-
Reporting and Data System (BI-RADS) categories are summarized in 
Table 1. Of 9,068 breast masses, 4,408 lesions (48.6%) were less 
than 10 mm, and the most common indication for biopsy was the 
presence of a BI-RADS category 4a lesion (54.0%, 4,900 of 9,068). 
Three CNBs were BI-RADS category 1; among these, two cases were 
regarded as normal breast tissue on US, but the patient requested a 
biopsy. The remaining such case was a patient who had undergone a 
mastectomy and showed normal breast tissue on US, but a positron 
emission tomography scan revealed increased fluorodeoxyglucose 
uptake. All three cases were identified as benign on pathologic 
reports after the biopsies.
Pathologic Results and Underestimation Rate of CNB
Among the 9,068 breast masses, the pathologic results of US-
guided 14-gauge CNB were benign in 64.2% (5,821 lesions), high-
risk in 3.5% (322 lesions), and malignant in 32.3% (330 DCIS 
lesions and 2,595 cases of invasive cancer) (Tables 2, 3). A total 
of 4,782 cases were confirmed by surgical excision or US-guided 
vacuum-assisted biopsy; in these cases, breast cancer was found in 
3.2% (63 of 1,990) of benign CNBs, 26.3% (79 of 300) of high-risk 
CNBs, and 100% (2,492 of 2,492) in malignant CNBs at the final 
diagnosis. The malignancy rates were 0% (0 of 3) for lesions in BI-
RADS category 1, 2.8% (1 of 35) in category 2, 2.2% (28 of 1,248) 
in category 3, 9.4% (463 of 4,900) in category 4a, 47.7% (267 of 
560) in category 4b, 83.9% (640 of 762) in category 4c, and 97.8% 
(1,526 of 1,560) in category 5. The underestimation rate was 33.6% 
(111 of 330) for DCIS and 24.5% (79 of 322) for high-risk lesions at 
surgical excision (Fig. 1). 
False-Negative Results
Of the 5,821 benign CNB results, 63 lesions were confirmed to be 
malignant after surgical excision (1.1%, 63 of 5,821). After post-
biopsy review, 5,586 benign CNBs showed imaging-pathology 
concordance, which included 29 lesions that were ultimately 
diagnosed as malignant (0.5%, 29 of 5,586), while 235 benign 
CNBs showed imaging-pathology discordance (Fig. 2), including 34 
lesions determined to be malignant after the subsequent surgical 
excision (14.4%, 34 of 235). A total of 3,067 cases were malignant 
at the final diagnosis, and the false-negative rate was 2.0% (63 of 
3,067) with a sensitivity of 95.4% (2,927 of 3,067). Of the false-
negative results, papillary lesions represented the highest percentage 
(36.5%, 23 of 63), followed by fibrocystic changes (20.6%, 13 
Table 1. Distribution of the size and BI-RADS categories of lesions assessed using US-guided 14-gauge core needle biopsy
Size (mm)
BI-RADS category
Total
1 2 3 4a 4b 4c 5
≤10 0 17 (0.4) 621 (14.1) 3,157 (71.6) 230 (5.2) 215 (4.9) 168 (3.8) 4,408
10 to ≤20 2 (0.1) 6 (0.2) 415 (14.2) 1,321 (45.3) 213 (7.3) 346 (11.9) 613 (21.0) 2,916
20 to ≤30 0 4 (0.4) 120 (11.5) 285 (27.3) 67 (6.4) 135 (12.9) 433 (41.5) 1,044
30 to ≤40 1 (0.3) 4 (1.0) 54 (13.5) 84 (21.1) 32 (8.0) 36 (9.0) 188 (47.1) 399
>40 0 4 (1.3) 38 (12.6) 53 (17.6) 18 (6.0) 30 (10.0) 158 (52.5) 301
Total 3 (0.1) 35 (0.4) 1,248 (13.7) 4,900 (54.0) 560 (6.2) 762 (8.4) 1,560 (17.2) 9,068
Values are presented as number (%).
BI-RADS, Breast Imaging-Reporting and Data System; US, ultrasonography.
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mean time interval between the initial CNB and excision was 11.6 
months (range, 5 to 17 months) (Table 4). For five benign lesions, 
although radiologists performed imaging-pathology correlations 
and recommended surgical excision immediately after the initial 
CNB, the patients refused excision, resulting in delayed diagnoses 
of malignancy. All 10 delayed false-negative diagnoses showed 
progression in follow-up US imaging (Fig. 3). Of the five cases in 
which excision was refused, one lesion (Table 4, patient 1) was 
of 63) and fibrosis (9.5%, 6 of 63) (Table 2). Most false-negative 
diagnoses (84.1%, 53 of 63) underwent immediate rebiopsy (interval 
range, 3 to 79 days; mean, 31.1 days) because the radiologist 
noted the discordance between the imaging findings and CNB and 
recommended surgical excision or a vacuum-assisted biopsy. 
Analysis of Delayed False-Negative Diagnoses
Ten malignancies (15.9%, 10 of 63) had delayed diagnoses, and the 
Fig. 1. Ductal carcinoma in situ in a 31-year-old woman.
A, B. Transverse (A) and longitudinal (B) ultrasonography shows an oval microlobulated mass (arrows) categorized as BI-RADS category 4a. 
The result of ultrasound-guided core needle biopsy was atypical ductal hyperplasia, which was considered to be concordant. Surgical excision 
was recommended due to the high-risk pathology, and ductal carcinoma in situ was confirmed by excision. BI-RADS, Breast Imaging-
Reporting and Data System.
A B
Table 2. Pathological results of benign lesions on US-guided 14-gauge core needle biopsy correlated with the standard diagnostic 
reference
Core needle biopsy
Standard diagnostic reference
Total
Benign DCIS Invasive
Benign 5,758 (98.9) 41 (0.7) 22 (0.4) 5,821
Fibrocystic change 1,674 (99.2) 8 (0.5) 5 (0.3) 1,687
Fibroadenoma 887 (99.8) 1 (0.1) 1 (0.1) 889
Fibroadenomatous hyperplasia 747 (99.7) 0 2 (0.3) 749
Papilloma 705 (96.8) 17 (2.4) 6 (0.8) 728
Fibrosis 639 (99.1) 4 (0.6) 2 (0.3) 645
Adenosis 350 (98.6) 5 (1.4) 0 355
Ductal epithelial hyperplasia 162 (97.0) 3 (1.8) 2 (1.2) 167
Duct ectasia 158 (100) 0 0 158
Inflammation 77 (100) 0 0 77
Fat necrosis 40 (97.6) 1 (2.4) 0 41
Galactocele 25 (100) 0 0 25
Foreign body reaction 20 (100) 0 0 20
Other benign 274 (97.9) 2 (0.7) 4 (1.4) 280
Values are presented as number (%).
US, ultrasonography; DCIS, ductal carcinoma in situ.
US-guided core biopsy of breast
e-ultrasonography.org Ultrasonography 37(1), January 2018 59
categorized as BI-RADS category 4a and the result of the initial US-
guided CNB was fibrocystic change, which was considered to be 
concordant. However, a radiologist recommended surgical excision 
because of its large size (30 mm); the lesion increased in size from 
30 to 43 mm over 17 months, and was confirmed as a malignant 
phyllodes tumor following surgical excision. Another patient (Table 
4, patient 8) had a history of breast surgery due to intraductal 
papilloma 13 years ago, and a new mass was categorized as BI-
RADS category 4a. The result of CNB was focal fibrosis, but a 
radiologist concluded that the lesion had high possibility of being 
intraductal papilloma and recommended surgical excision. The lesion 
markedly increased in size from 24 to 50 mm over 17 months, and 
was confirmed as invasive lobular carcinoma following surgical 
excision. Both of these patients refused excision after the initial 
CNB, causing delayed diagnoses of malignancy.
Discussion
In this study, we analyzed a large population in which US-guided 
CNBs of breast lesions were performed from July 2005 to December 
2012, building upon the previous study conducted from February 
2000 through June 2005 at our institution [5]. The inclusion 
criteria were the same in both studies, and we included a total of 
9,068 breast masses in this study, in contrast to 2,420 masses in 
the previous study. The mean lesion size was smaller in this study 
(mean, 14.0 mm; range, 2 to 130 mm) than in the previous study 
(mean, 18.7 mm; range, 2 to 180 mm), but we showed a lower 
false negative rate of 2.0% (63 of 3,067) than the false-negative 
Table 3. Pathological results of high-risk and malignant lesions on US-guided 14-gauge core needle biopsy correlated with the 
standard diagnostic reference
Core needle biopsy
Standard diagnostic reference
Total
Benign DCIS Invasive
High-risk 243 (75.5) 41 (12.7) 38 (11.8) 322
Atypical ductal hyperplasia 62 (48.8) 40 (31.5) 25 (19.7) 127
Possible phyllodes tumor 149 (91.4) 1 (0.6) 13 (8.0) 163
Radial scar, lobular neoplasia 32 (100) 0 0 32
Malignant 0 234 (8.0) 2,691 (92.0) 2,925
DCIS 0 219 (66.4) 111 (33.6) 330
Invasive cancer 0 15 (0.6) 2,580 (99.4) 2,595
Values are presented as number (%).
US, ultrasonography; DCIS, ductal carcinoma in situ.
Table 4. Delayed false-negative diagnoses after US-guided 14-gauge core needle biopsy
Patient No. BI-RADS category Core needle biopsy result Final diagnosis
Interval between initial core needle biopsy 
and excision (mo)
1a) 4a Fibrocystic change Malignant phyllodes tumor 17
2a) 4a Intraductal papilloma DCIS 11
3 4a Epidermal cyst Metaplastic carcinoma 9
4 4b Fibroadenomatous 
hyperplasia
Malignant phyllodes tumor 12
5 4a Stromal fibrosis Papillary carcinoma 9
6a) 4b Fibroadenoma Low grade adenosquamous carcinoma 5
7 4a Fibroadenomatous 
hyperplasia
Invasive ductal carcinoma 12
8a) 4a Focal fibrosis Invasive lobular carcinoma 17
9 3 Almost fatty tissue DCIS 7
10a) 4a Intraductal papilloma Intraductal papillary carcinoma 17
US, ultrasonography; BI-RADS, Breast Imaging-Reporting and Data System; DCIS, ductal carcinoma in situ.
a)The radiologist recommended surgical excision immediately after the initial core needle biopsy, but the patient refused excision, resulting in a delayed false-negative diagnosis.
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rate of 2.4% (31 of 1,312) observed in the previous study. Overall, 
the results of our study showed that US-guided 14-gauge CNB for 
breast lesions exhibited better performance, based on the analysis 
of a larger population with smaller lesions in contrast to the sample 
of the preceding study from the same institution.
False-negative diagnoses are unavoidable for reasons such as 
sampling errors, failure to act upon imaging-histology discordances, 
or the absence of imaging follow-up after a benign biopsy [9]. 
However, most false-negative diagnoses can be immediately 
recognized through careful post-biopsy review, as was exemplified 
by our data. Most of our false-negative results (84.1%, 53 of 63) 
underwent immediate rebiopsies, avoiding delayed diagnoses of 
cancer, because imaging-pathology discordances were promptly 
detected by radiologists. Previous studies have shown similar 
Fig. 2. Invasive ductal carcinoma in a 51-year-old woman.
A, B. Transverse (A) and longitudinal (B) ultrasonography shows a microlobulated hypoechoic mass (arrows) categorized as BI-RADS category 
4b. The result of ultrasound-guided core needle biopsy was fibrocystic change, which was considered to be discordant. Vacuum-assisted 
biopsy was recommended immediately and invasive ductal carcinoma was confirmed by vacuum-assisted biopsy.
A B
Fig. 3. Invasive lobular carcinoma in a 75-year-old woman.
A, B. Ultrasonography shows a solid and cystic mass (arrows) (A) categorized as BI-RADS category 4a. The result of ultrasound-guided core 
needle biopsy was focal fibrosis. After 17 months, the mass increased in size from 24 to 50 mm (arrows) (B). Surgical excision was performed 
and invasive lobular carcinoma was confirmed.
A B
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results [5,6,13,18]. Several studies have suggested that physicians 
should perform rebiopsies or surgical excision for discordant 
CNBs because of the high prevalence of carcinoma in imaging-
pathology discordant lesions [15,19,20]. Our data likewise showed 
a much higher malignant rate of 14.4% in discordant benign 
CNBs, which is within the 6.8%-24.4% range reported in previous 
studies [15,19,21], compared with a malignancy rate of 0.5% in 
concordant benign CNBs. These results accentuate the importance 
of imaging-pathology correlations after biopsy and the significance 
of discordant lesions. 
Of the false-negative diagnoses, papillary lesions comprised the 
largest subgroup (36.5%, 23 of 63) in terms of the histological 
classification, and 3.1% (23 of 728) of the papillary lesions that 
underwent CNB were upgraded to malignancy; this is comparable 
with previous studies, in which 2.3%-14% of papillary lesions were 
upgraded to DCIS or invasive cancer after surgical excision [22-
26]. To decide whether a papillary lesion is benign or malignant 
on the basis of CNB is challenging because of the heterogeneity 
of papillomas and targeting error [27,28]. It remains controversial 
whether all benign papillary lesions on CNB should undergo surgical 
excision to avoid false-negative diagnoses. Our data showed an 
upgrade rate to carcinoma of only 2.3% (16 of 686) in concordant 
papillomas, in contrast to an upgrade rate of 16.6% (7 of 42) in 
discordant papillomas; this supports the suggestions of recent 
reports that observation is sufficient, rather than surgical excision, 
for papillomas identified as benign by CNB if the imaging-pathology 
findings are concordant [26,29].
Ten malignancies had delayed diagnoses without immediate 
rebiopsies in the false-negative results. All these lesions showed 
progression in follow-up US. After review of the patients’ medical 
records, we found that patients refused excision for five false-
negative lesions, although radiologists performed imaging-
pathology correlations for these lesions and recommended 
surgical excision immediately after the initial CNB. The other five 
delayed false-negative diagnoses were identified as malignancies 
on follow-up sonography within 1 year after the initial CNB. Our 
results suggest that it is important to consider not only appropriate 
follow-up, but patient compliance after the biopsy. In previous 
studies, compliance rates of only 54% (49 of 90 lesions) [30] 
and 50.9% (84 of 165 lesions) [31] were reported for imaging 
surveillance recommendations. Therefore, poor patient compliance 
and inappropriate follow-up may cause further delays in the 
diagnosis and treatment of breast cancer, even if imaging-pathology 
discordances are recognized immediately. 
One of the limitations of CNB is the histologic underestimation 
of breast malignancy, which means that lesions found to be high-
risk or DCIS by a percutaneous breast biopsy are upgraded to DCIS 
or invasive cancer after surgical excision. In previous studies, the 
underestimation rates ranged from 6.25% to 65% for ADH and 
from 16% to 66% for DCIS using CNB or vacuum-assisted biopsy 
[13,32-35]. Our underestimation rates were 24.5% for high-risk 
lesions (79 of 322) and 33.6% for DCIS (111 of 330), comparable 
with previous reports.
Our study has a few limitations. First, there was no retrospective 
pathologic review of the core needle samples for the false-negative 
results. Second, the radiologists who performed the biopsies were 
heterogeneous, and included radiologists undergoing fellowship 
training (n=15). However, our institution is a tertiary hospital 
and it is natural for less experienced trainees to perform biopsies. 
Furthermore, our results showed reliable sensitivity (95.4%) and a 
low false-negative rate (2.0%).
In conclusion, US-guided 14-gauge CNB is accurate and provides 
optimal diagnostic information for breast lesions. Imaging-histology 
correlations and appropriate imaging follow-up should be performed 
to identify possible false-negative results and to avoid delayed 
diagnoses.
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